EyePoint Pharmaceuticals (EYPT) Reports First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for Treatment of Wet AMD
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq lags peers as Netflix, chip stocks drag; AmEx lifts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Wall St indexes split, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Jabil falls after placing CEO on paid leave amid internal investigation
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
EyePoint Pharmaceuticals (EYPT) Announces Proposed Common Share Offering
February 1, 2021 4:04 PM ESTEyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by EyePoint. The offering is subject to market... More
After-Hours Stock Movers 01/27: (EYPT) (AGTC) (NOW) Higher; (AMC) (AXDX) (EXPR) Lower (more...)
January 27, 2021 6:05 PM ESTAfter-Hours Movers
AMC Entertainment Holdings, Inc. (NYSE: AMC) 25.4% LOWER; profit-taking after rising 301% intra-day Wednesday on short-squeeze
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) 9% HIGHER; Cantor Fitzgerald initiates with an Overweight rating and price target of $22.00.
Accelerate... More
Cantor Fitzgerald Starts EyePoint Pharmaceuticals, Inc. (EYPT) at Overweight
January 27, 2021 4:03 PM ESTCantor Fitzgerald analyst Jennifer Kim initiates coverage on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) with an Overweight rating and price target of $22.00.
The analyst comments "We are initiating coverage of EYPT shares with an Overweight rating and a 12-month PT of $22 using DCF analysis.... More
